Cantor Fitzgerald released a research report on July 25, 2026, trimming the target price for Celldex Therapeutics.
6 reports, 1 independent
Updated Sat 00:00
Mostly repetition
- Reports
- 6
- Developments
- 1
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald released a research report on July 25, 2026, trimming the target price for Celldex Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Celldex Therapeutics
American biopharmaceutical company
Nothing else this week.
Related events
- Analyst provides a high price target for Viking Therapeutics stock.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Market analysis compares Celldex Therapeutics and Seres Therapeutics.
- Cantor Fitzgerald lifted its price target for ARS Pharmaceuticals, Inc. on June 1, 2026.
Coverage
Newest first; wire copies grouped- tickerreport.comCantor Fitzgerald Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $61.00